Acquisition Synergy SeQure DX was acquired by MaxCyte in January 2025 to form the core of MaxCyte’s CGT Services, creating an integrated offering that combines cell engineering with comprehensive gene editing risk assessment. This signals enhanced cross-sell opportunities to MaxCyte’s existing and prospective CGT clients seeking end-to-end solutions.

Integrated Portfolio Joint positioning with MaxCyte enables a combined suite of cell engineering and off-target risk assessment services, presenting a compelling value proposition for therapeutic developers aiming to mitigate risk from discovery through clinical stages and regulatory submission.

Growth via Innovation Recent launches of advanced off-target nomination assays (CHANGE-seq-BE and ONE-seq-BE) by MaxCyte indicate ongoing commitment to expanding the risk assessment toolkit, creating upsell opportunities for existing clients and attracting new customers seeking cutting-edge analytics.

Financial Signals MaxCyte’s revenue trajectory and strategic partnerships in 2026, including gene delivery collaborations and commercial momentum in related CGT segments, suggest a robust upswing in demand for integrated analytics and cell engineering services, which can be leveraged to propose expanded engagement with potential clients.

Targeted Outreach With a small standalone team (2-10 employees) at SeQure DX but strong corporate backing, there is an opportunity to target mid-to-large biotechs and pharma developers actively pursuing ex vivo cell therapy programs, offering a seamless path from discovery to regulatory-ready outcomes through the combined MaxCyte ecosystem.